SCHEMBL16214743

SCHEMBL16214743

CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(C)c(O)ccc3nc2-1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TOP1 P11387 18/20 0.80
▸ MEN1 O00255 6/20 0.80
▸ KMT2A Q03164 6/20 0.80
▸ SMN1; SMN2 Q16637 5/20 0.80
▸ ALDH1A1 P00352 3/20 0.80
▸ RECQL P46063 2/20 0.80
▸ TDP1 Q9NUW8 2/20 0.80
▸ GLA P06280 2/20 0.80
▸ KDM4E B2RXH2 5/20 0.78
▸ CASP1 P29466 3/20 0.78
▸ CASP7 P55210 3/20 0.78
▸ HBB P68871 3/20 0.78
▸ MAPT P10636 3/20 0.78
▸ USP2 O75604 2/20 0.78
▸ LMNA P02545 2/20 0.78
▸ BRCA1 P38398 2/20 0.78
▸ KEAP1 Q14145 2/20 0.78
▸ NFE2L2 Q16236 2/20 0.78
▸ HIF1A Q16665 2/20 0.78
▸ CYP3A4 P08684 2/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18251452 1.00 TOP1 (0.80) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL27170416 0.92 TOP1 (0.81) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL27603460 0.91 TOP1 (0.85) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6599316 0.91 TOP1 (0.85) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL23432348 0.91 TOP1 (0.79) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL27818301 0.91 TOP1 (0.79) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL27170420 0.91 TOP1 (0.79) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7258182 0.91 TOP1 (0.79) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5325716 0.91 TOP1 (0.79) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL18251457 0.91 TOP1 (0.79) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3095785-B1 SYNTHESIS METHOD OF 9-ALLYLCAMPTOTHECIN DERIVATIVES SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) 2018-02-07 — — EP disclosed
US-20150196654-A1 Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity IMMUNOMEDICS, INC. 2015-07-16 — — US disclosed
US-8877901-B2 Camptothecin-binding moiety conjugates IMMUNOMEDICS, INC. (US) 2014-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150196654-A1 Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity CD74, CD2, CD22 TOP1 375/4885MEN1 3014/4885KMT2A 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback